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Proton therapy is actively and repeatedly discussed within the framework of particle 
therapy for the treatment of prostate cancer (PC). The argument in favor of treating the 
prostate with protons is partly financial: given that small volumes are treated, treatment 
times are low, resulting in a hypothetical high patient throughput. However, such consid-
erations should not form the basis of medical decision-making. There are also physical 
and biological arguments which further support the use of particle therapy for PC. The 
only relevant randomized data currently available is the study by Zietman and colleagues, 
comparing a high to a low proton boost, resulting in a significant increase in PSA-free sur-
vival in the experimental (high dose) arm (1). With modern photon treatments and image-
guided radiotherapy (IGRT), equally high doses can be applied with photons and, thus, 
a randomized trial comparing high-end photons to protons is warranted. For high-linear 
energy transfer (LET) particles, such as carbon ions, the increase in relative biological 
effectiveness could potentially convert into an improvement in outcome. Additionally, 
through the physical differences of protons and carbon ions, the steeper dose gradient 
with carbon ions and the lack of beam broadening in the carbon beam lead to a superior 
dose distribution supporting the idea of hypofractionation. Biological and clinical data are 
emerging, however, has practice-changing evidence already arrived?
Keywords: protons, prostate cancer, carbon ions, clinical trials, iMRT
iNTRODUCTiON
Proton beam therapy (PBT) among particle therapy for prostate cancer (PC) remains a highly 
topical subject in the uro-oncological community. It is fueled by discussions concerning question-
able superiority to photon treatment with regard to survival or local control, higher costs and 
cost-effectiveness, better tolerance for patients due to fewer side effects, and, last but not least, 
continuous patient inquiries regarding the therapy (2). This is represented by numerous ongoing 
trials and publications; the search for “proton therapy AND PC” on clinicaltrials.gov generates 36 
FiGURe 1 | Characteristic dose profile for photons (green), protons 
(yellow), and carbon ions (black). Typical Bragg Peak (red) for particles 
that can be directed into defined regions depending on the energy used 
[adapted from Combs et al. (7)].
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hits alone (3). As biological and clinical data are emerging, the 
question remains: has practice-changing evidence already been 
uncovered?
PHOTONS
The goal in radiotherapy (RT) of localized PC is a lethal dose 
to tumor cells, while ensuring that the smallest possible dose is 
applied to surrounding tissues, such as rectum and bladder, and 
thereby avoiding side effects and toxicities for patients.
Nowadays photons are the most commonly used treatment in 
RT for PC. Photons have no mass and no charge and, therefore, 
travel easily through target materials. There is an initial increase 
of energy as they interact with the target material electrons (e.g., 
the body), which enhances the radiation effect. As a result of this, 
their peak dose is reached within a few centimeters from the 
entrance surface – the so-called “dose accumulation effect.” In the 
deeper trajectory through the body subsequently, the radiation 
dose decreases until it exits the body. 3D plans initially had a sig-
nificant dose deposition in the entry and exit fields. With multiple 
field plans, rapid arc or helical techniques, these doses tend to be 
significantly smaller, but often a dose bath with low-to-moderate 
doses over surrounding organs cannot be avoided in order to 
deliver a deathly dose to cancer cells (4). The possible side effects 
include gastrointestinal (GI) and genitourinary (GU) problems 
and a potentially slightly higher risk for secondary malignan-
cies (5). Therefore, photon radiation therapy does not seem 
appropriate in terms of its physical characteristics to treat those 
organs located at a great depth within the body. Despite modern 
improvements in technologies, such as multi-leaf collimators, 
intensity-modulated radiotherapy (IMRT), or image-guided 
radiotherapy (IGRT), photon-beam therapy will always include a 
certain level of entrance and exit doses, resulting in healthy tissue 
receiving low-to-moderate radiation doses. While these doses are 
most likely not associated with a prominent side effect risk, such 
issues necessitate a serious consideration of alternative treatment 
options, including particle therapy.
PARTiCLe THeRAPY
As of 2013, more than 123,000 patients had received therapy with 
heavy particles worldwide, PBT accounting for the majority of 
this, with over 106,000 patients treated (6). While protons can 
be termed particles, they are not considered “heavy,” and from 
their effect they can be categorized as low-linear energy transfer 
(LET) radiation, comparable to photons. Heavy particles include 
carbon ions, oxygen as well as neutrons, and others. Particles 
may be charged (protons, carbon ions) or neutral (neutrons). The 
term “heavy particle therapy” is generally used to distinguish it 
from conventional X-Ray RT, which uses massless photons. As 
most research undertaken so far has investigated protons, we 
shall mainly focus on them in the following article. Experience 
with other heavy particles is limited to a mere seven operating 
carbon ion facilities worldwide, treatment with carbon ions can 
be considered experimental and, therefore, reliable evidence is 
only just emerging and no conclusions can yet be drawn with 
regard to their effectiveness or toxicity.
PROTONS
Due to their physical characteristics, protons potentially offer a 
treatment method in which smaller areas receive radiation doses 
and, thus, bring about fewer side effects. Proton beams are created 
by a cyclotron or synchrotron, whereby the proton is separated 
from hydrogen molecules. Protons travel fast through tissue, with 
minimal room for interaction; in depth the velocity is reduced, 
interactions occur, and the energy is deposited: they, therefore, 
stop very abruptly in tissues reaching a very specific depth: the 
so-called “Bragg peak” (7), see Figure  1. Here, the majority of 
energy is being deposited. Heavy particles, compared to photons, 
have a greater radiobiological effect (1.1 times for protons and 
2–3 for carbon ions) and, therefore, greater potential to damage 
cancer cells by interacting more densely with tissue, causing 
higher levels of ionization per unit length (8, 9). The dose then 
rapidly decreases to 0 as heavy particles (opposed to photons) 
stop within the body. Thus, the integral dose with protons is 
approximately 60% lower than that of any external beam photon 
technique (10, 11).
In theory, this is ideal for treating tumors near to sensitive 
structures, such as the brain and spinal cord, as well as for child-
hood cancers in order to reduce the dose to healthy surrounding 
organs. PBT can potentially show a clinical superiority compared 
to photons and is, to a certain extent, established in some popula-
tions such as pediatric indications or uveal melanoma, at least in 
some regions worldwide (12–14).
It is important in all populations to note that RT comes with 
the risk of developing secondary malignancies years to decades 
later. Although this risk is low with modern techniques, it is 
in focus for radiation oncologists, and patients alike. With the 
sharp dose deposition of particles, there are presumably a smaller 
number of secondary malignancies due to the lower dose to sur-
rounding healthy structures. Nevertheless PBT, as opposed to 
photon therapy, generates neutrons as a by-product, which can 
FiGURe 2 | individualized radiotherapy (iRT): prostate cancer patient 
stratification for different radiation modalities.
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be scattered into adjacent normal tissues, especially with passive 
beam techniques. These neutrons have a strong biological effect 
and, thus, could theoretically increase the risk of secondary 
malignancies (15). Despite such theoretical concerns, a large 
retrospective study did not find statistically significant differences 
in secondary malignancies between patients treated with protons 
and those treated with photons – 5.2% of all PBT-treated patients 
had secondary malignancies versus 7.5% in the photon treatment 
group (16).
The width of the Bragg peak is within the millimeter range 
and usually not wide enough to cover a whole treatment volume. 
Several of those peaks must be superimposed to treat effectively a 
tumor of a certain length and volume – the so-called “spread-out 
Bragg peak” (SOBP). There can be some uncertainty about the 
exact location of the Bragg peak due to tissue inhomogeneities. 
Here, PBT skeptics argue that there is no widely used method for 
confirming the proton range, or that the SOBP encompasses the 
prostate in  vivo, making sufficient margins essential for a suc-
cessful therapy and thereby diminishing the possible advantage 
of smaller radiation volumes.
Another technical challenge is that, because of the steep dose 
gradient (Bragg peak), the plan parameters and patient position-
ing must be highly precise in order to obtain a high dose within 
the tumor region while maximizing the protection of organs at 
risk (OAR). This makes the uncertainty regarding the range of 
motion in human tissue one of the major hurdles of RT with pro-
tons, meaning that particle therapy is more vulnerable to target 
motion than photon irradiation (17).
Yoon et  al. also describe an increased sensitivity to target 
motion of PBT because of deep dose depletion beyond the 
SOBP (18).
In RT of PC, the range of motion can be divided into inter- 
and intrafractional movements. Interfractional movements 
occur between two radiation appointments, e.g., due to filling 
of the bladder and rectum. Intrafractional movements happen 
within one radiation session, e.g., due to breathing, bowel gas, 
or small patient movements. Because of this, measurements 
in PBT should be made even during dose delivery and can be 
accomplished via positron emitters (PET camera) or induced 
gamma radiation (Compton camera) (19, 20). Motion mitigation 
strategies are essentially important to exploit the full potential 
of particle therapy; this includes scanning approaches, such as 
rescanning, gating, or implementation of motion-surrogates, 
such as markers (21–23).
CARBON iONS
As opposed to protons, which can be considered to have 
radiobiological features similar to photons [relative biological 
effectiveness (RBE) = 1.1 for protons], other heavy particles have 
higher LET characteristics, leading to substantial differences 
in radiobiological interactions. Due to their mass, carbon ions 
have a higher biological effectiveness compared to protons with a 
comparable depth-dose profile. The RBE of the carbon ion beams 
has been estimated as 2.0–3.0 (9). This means that they are twice 
to three times more effective in killing cancer cells than proton 
or photon beams as they are more likely to cause deathly DNA 
double-strand breaks. Thus, carbon ions have radiobiological 
advantages, including more effective killing of intrinsic radio-
resistant tumors, hypoxic tumor cells, and tumor cells in the G0 
or S phase (24).
Furthermore, they possess an even sharper dose distribution 
than protons, but the dose in the region beyond the distal end 
of the peak is higher in carbon ion beams than proton beams, 
because carbon ions undergo nuclear interactions producing a 
fragmentation tail beyond the dose peak (25, 26).
In terms of its medical application, carbon ion therapy has been 
described as being advantageous inter alia for PC. Regarding the 
anti-tumor effect of carbon ion RT for PC, Ishikawa et al. reported 
survival data and biochemical relapse-free rates for almost 1000 
patients with 20 or 16 fractions at the ion beam center in Chiba, 
Japan. The 5-year overall survival and cause-specific survival 
rates for all patients were 95.3 and 98.8%, respectively; the 5-year 
relapse-free and local control rates were 90.6 and 98.3%, respec-
tively. Especially noteworthy is that the outcomes for biochemical 
relapse-free survival also included the high-risk group and that 
hypo-fractionated carbon ion RT seems to have had radiobio-
logical benefit for PC (24, 27). In a more recent Phase I/II study 
from 2014, Nomiya et al. described a shortened course with only 
12 fractions as another feasible option, however, the long-term 
outcome of such an approach is still pending (28).
Certainly, there are advantages of carbon ion RT, as an option 
with high biological effectiveness over low-LET radiations, such 
as photon therapy or PBT, and carbon ion therapy may prove 
to make a substantial difference in certain patient populations. 
However, precise definition of clinical study protocols and criti-
cal evaluation of patient data together with intake of molecular 
characteristics of tumors and normal tissue can help to optimally 
stratify patients for different radiation modalities leading to 
individualized radiotherapy (iRT). (Figure 2).
TeCHNOLOGiCAL ASPeCTS
Common passive scattering systems will be replaced by spot 
scanning systems in charged particle beam therapy in medium 
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term. It is in routine clinical use at the Paul Scherrer Institute 
(PSI) in Darmstadt. Advantages are the precise dose distribution 
and planning options for using intensity-modulated proton beam 
therapy (IMPT). The application is safe but several aspects for 
uncertainties, such as the robustness to movements of the target 
and to IMPT plans, must be taken into account when working 
with spot scanning techniques. Zhu et al. reported on the single-
field integrated boost (SFIB) technique for spot scanning proton 
therapy based on single-field optimization (SFO) treatment plan-
ning techniques (29).
Regarding beam delivery, most experience has mainly been 
acquired with horizontal beam lines. The success of radiotherapy 
treatment is strongly increased through the possibility of applying 
the beam to the target using different angles, such as in IMRT. 
Hence, the worldwide first gantry for charged particle was 
brought online in October 2012 at the Heidelberg Ion Therapy 
Center (HIT), Heidelberg.
DiSCUSSiON
The success of irradiation in patients with localized PC correlates 
with the administered dose, meaning that a higher dose to the 
prostatic gland leads to better cancer control (1).
Several randomized trials have shown a benefit of dose 
escalation to 78–79 Gy for men treated with external radiation 
for localized PC. Previous data suggested a benefit with even 
higher doses. In a trial by Coen et al., the safety and efficacy 
of 82  Gy (a 2  Gy equivalent) delivered with conformal PBT 
was tested. The estimated rate of ≥Grade 3 late toxicity at 
18 months was 6%, indicating that this may be the maximal 
dose that can be delivered safely with this technique and 
fractionation (30).
On the other hand, with new techniques such as IMRT (± 
rapid arc) or IGRT, photon radiation encumbers OAR with 
low-to-moderate doses. Such doses normally do not cause 
noticeable side effects for patients, and photon therapy has 
reached a high level of patient comfort and acceptance. In a 
similar way, IMRT is described to have excellent efficacy and 
low toxicity in the treatment of PC, even with elevated final 
doses (31, 32).
It has, thus, become the standard procedure for RT of PC in 
many institutes due to the significantly reduced toxicities compared 
with what has been observed with conventional 3D-approaches.
The feasibility of high-dose IMRT (up to 81  Gy) has been 
demonstrated in studies with large numbers of patients and has 
been proven to have comparably low side effects (33–35).
This was stated earlier by Mock et al.: they described IMRT 
as more effectively enabling dose reductions to OAR in the 
medium dosage range compared to 3D conformal radiotherapy. 
Furthermore, they indicated possible benefits of the two-field 
PBT technique, which reduces doses to surrounding tissues 
compared to photon-beam RT (36). The physical properties of 
protons may, thus, decrease common GI and GU side effects 
even further.
As early as 1983, Duttenhaver et al. discussed proton versus 
a conventional megavoltage X-Ray (photon) boost, finding no 
difference in local tumor control (LC), disease-free survival 
(DFS), or overall survival (OS), yet fewer side effects with an 
elevated proton boost. Photon RT has evolved since then, as 
described above, with numerous technical advances, while PBT 
has yet to prove itself through better LC, OS, or significantly fewer 
side effects (37).
In dosimetric studies of a small patient group Vargas et al. were 
able to show a reduced mean rectal (59%) and bladder (35%) dose 
for PBT compared to IMRT (38). Early outcomes from single 
arm, prospective trials confirmed these assumptions. Nihei et al. 
described the incidence of late ≥grade 2 rectal and bladder toxic-
ity at 2 years to be 2.0 and 4.1%, respectively (39).
Similarly, Mendenhall et al. found good early outcomes with 
image-guided proton therapy, suggesting high efficacy and mini-
mal toxicity with 1.9% grade 3 GU symptoms and <0.5% grade 
3 GI toxicities (39, 40). Generally, the dose to healthy tissues in 
the range <50% of the target prescription was substantially lower 
with proton therapy (41).
A retrospective analysis of the Medicare database compared 
early toxicity in 421 men using PBT with 842 matched controls 
treated with IMRT. A statistically significant decrease in GU 
toxicity at 6  months for PBT was seen, but this difference had 
disappeared at one year. There were no other significant dif-
ferences in toxicity between the two techniques at either 6 or 
12 months post-treatment. Yu et al. concluded that although PBT 
is substantially more cost-intensive than IMRT, no difference in 
toxicity in a comprehensive cohort of Medicare beneficiaries with 
PC at 12 months post-treatment was found (42).
Keeping in mind that the amount of bladder exposed to low 
doses of radiation predicts early toxicity the difference in toxic-
ity seen by Yu et al. is plausible, since in previous studies it has 
been shown that one improvement in radiation dose distribution 
for PBT compared to IMRT led to a reduction in the amount of 
bladder exposed to low and intermediate levels of radiation (36, 
41, 43). This dose reduction was most likely responsible for the 
transient improvement in the Yu study.
However, other studies have found IMRT to be favorable 
over PBT with regard to toxicity. An analysis from the Medicare 
Surveillance, Epidemiology, and End Results (SEER) database in 
the USA identified 684 men treated with PBT between 2002 and 
2007 and compared these with a cohort treated with IMRT.
Intensity-modulated radiotherapy was associated with sig-
nificantly less GI morbidity. However, there were no statistically 
significant differences in other toxicities, nor a significant differ-
ence in the frequency with which patients required additional 
cancer therapy (44).
There are still no completed randomized trials comparing 
PBT with photon-beam therapy in men with clinically localized 
PC (45).
With regard to the OS data, a few major studies have been 
conducted. One of the major dose-escalation studies was carried 
out at The Proton Center in Boston. Zietman et al. randomized 
393 patients with a PSA <5 ng/ml to a low-dose arm (50.4 Gy 
photon therapy + 19.8 GyE proton boost) and a high-dose arm 
(50.4 Gy photon + 28.8 GyE proton boost). The analysis revealed 
a significant difference in biochemical recurrence-free survival 
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in favor of the high-dose arm. Subgroup analysis of low and 
high-risk patients (depending on the Gleason score) showed a 
significant advantage for the high-dose group in both cases. An 
impact on the OS rate was not observed. Both acute and late tox-
icities were not increased in either arm compared to the incidence 
of comparable photon studies (1, 46). However, modern photon 
treatments allow comparable high-dose application with utmost 
precision and safety; thus, the latter trial might be termed mainly 
not as a trial comparing photons and protons, but high-dose to 
low-dose treatments.
Finally, the American Society for Radiation Oncology 
(ASTRO) released a list recommending the use of PBT after 
an evidence-based review for certain tumors, including central 
nervous system and pediatric malignancies. For others, among 
them PC, it recommends treatment only within the setting of 
clinical trials, as there was evidence for the efficacy of PBT but no 
suggestion that it is superior to photon-based approaches (47, 48).
COST ASPeCT
Concerning costs, several aspects must be highlighted: the 
construction costs of proton facilities, maintenance costs and 
outcome, also concerning throughput compared to photon 
radiation.
First, Keener et al. estimated the building cost for a new PBT 
center to be between 100 and 250 million US-Dollars. This is the 
equivalent of about 40 times the price of setting up a state-of-the-
art photon radiation center (49).
As for maintenance and cost-effectiveness, Johnstone et  al. 
calculated that a high number (single gantry 85%) of “simple” 
cases with a faster throughput are necessary for proton facilities 
to work cost effectively (50).
Proton beam therapy for PC is often described as simple, 
compared to pediatric or central nervous system indications, 
where longer setup and/or treatment times are required. A mod-
ern proton center requires treating a caseload and emphasizing 
simple patients with high throughput even before operating costs 
or any profit are achieved (50). In theory, this means that a PBT 
facility treating only patients with PC would run cost effectively 
and profitably.
With regard to compensation, Yu et al. found median Medicare 
reimbursement in the USA to be over 32,000 US-Dollars for pro-
ton RT and over 18,000 for IMRT. In a retrospective study of over 
27,000 patients, they found no toxicity difference at 12 months 
post-treatment, despite the cost being almost double (42).
Furthermore, in a cost utility analysis per quality-adjusted life 
year (QALY) from a literature search between 2003 and 2013, 
PBT was not found to be cost-effective in any of the analysis (51).
A very interesting open phase 3 study (NCT01230866) is 
underway and could make a significant difference to PBT cost-
effectiveness, as well as to the life quality of patients. The study 
compares standard dose of RT (44 treatments) with a hypofrac-
tionation concept (five treatments) (52).
This study could dramatically decrease the treatment costs 
of PBT if the hypofraction arm performs similar or better than 
normofractionated treatment. It could also improve the life qual-
ity of patients as a result of the decreased number of treatment 
appointments. However, only recently the biological rationale 
of hypofractionation was revisited questioning the current α/β 
concepts – newer data assume that prostate α/β are, after all, more 
closely comparable to those of rectal or other normal tissue than 
initially believed, thus, questioning the real rationale of hypo-
fractionation (53).
In summary, technology for PC RT has made important 
advances. However, its associated costs have escalated, thus, 
making cost-effectiveness analysis critical to assess. So far, 
all aspects of PBT remain far more expensive than photon 
radiation therapy, meaning that cost consciousness should 
outweigh standard PBT for PC as long as there is no clear 
evidence from controlled randomized trials supporting the 
superiority of PBT, so that the surplus of money spent can be 
well-invested. However, data are available that proton therapy 
can be applied, and especially in the pediatric population 
referral to a high-end particle therapy center should be evalu-
ated. For carbon ions, patients should be treated within clini-
cal trials until the full potential and the biological rationale 
can be shown in patient treatments.
In conclusion, proton therapy is worth being discussed in 
modern oncology with assets leading to potentially advanta-
geous treatments; however, this should not lead to unreflected 
discussions and recommendations that proton therapy is the 
necessary independently of indication patient age, comorbidi-
ties, and other factors. For PC, it will be interesting to follow 
the ongoing research to see which technique “will be the road 
less traveled.”
CONCLUSiON
A high publication rate confirms continued high interest in PBT 
and its characteristics. Reading through such publications, one 
gets the impression that the authors often take a similar stance 
to ASTRO, who finished the abstract of their evidence-based 
review with the words: “More robust prospective clinical trials 
are needed to determine the appropriate clinical setting for 
PBT” (47).
There is much discussion and disagreement concerning tox-
icities, cost–effectiveness, and the potential for better outcomes 
(2). However, PBT is certainly cost-intensive and yet has great 
potential with regard to basic physics and biological principles. 
Nevertheless, the advantages so far seem to remain theoretical 
and are brought about by a better dose distribution.
Several trials are underway, among them a multi-institutional 
randomized phase III Nacional Cancer Institute study (A 
Phase III Randomized Clinical Trial of Proton Therapy Versus 
IMRT for low or intermediate risk PC; clinicaltrials.gov ID 
NCT01617161) comparing PBT to IMRT (54). It is now in its 
third year and, together with others, will hopefully shed some 
more light onto the discussion of PC and RT with photons and 
particles, which in the end will lead to individualized radio-
therapy (iRT) concepts.
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